Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Islet Sciences gets rights to remogliflozin from BHV

Executive Summary

BHV Pharma Inc. (Brighthaven Ventures) licensed Islet Sciences Inc. exclusive worldwide rights--excluding Japan, Korea, Taiwan, China, and Latin America--to develop and commercialize its Phase IIb SGLT2 inhibitor remogliflozin etabonate for Type II diabetes and nonalcoholic steatohepatitis (NASH).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • R+D and Marketing-Licensing

Related Companies

UsernamePublicRestriction

Register